France · Series A startup

Who invested in AbolerIS Pharma

One round we have observed, with the 0 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 31 Oct 2026

$29Mraised across 1 round since 2023, from 1 source

Latest round
Series A, $29MSept 2023
Investors
0
See who backed them

The rounds

  1. Sept 2023
    Series A$29M

    No investor was named in the report.

    Source recorded

Founders and team

From AbolerIS Pharma's own website: 5 on the team.

  • Philippe AlenChief Business Officer (ad intrim)
  • Tomas Van DyckCFO
  • Antoine ThomasHead of CMC
  • Benoit MoreauxHead of Operations
  • Professor Michel GoldmanBoard of Directors

Also claim to have backed them

These 3 firms list AbolerIS Pharma as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

SFPIMVC firmPer its own site
Newton BiocapitalVC firmPer its own site
Criteria Bio VenturesCorporate VCPer its own site

Quick answers about AbolerIS Pharma

How much has AbolerIS Pharma raised?

AbolerIS Pharma has raised $29M across 1 round since 2023.

When did AbolerIS Pharma last raise?

AbolerIS Pharma's most recent round was a Series A of $29M in Sept 2023.

What was AbolerIS Pharma's biggest round?

Its most recent round, $29M in Sept 2023, is also its largest on record.

What stage is AbolerIS Pharma at?

AbolerIS Pharma's latest named round is a Series A, in Sept 2023.

Where is AbolerIS Pharma based?

AbolerIS Pharma is based in France.

Companies like AbolerIS Pharma

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.